Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Guanyi He *Seattle Children's Research Institute, Norcliffe Foundation Center for Integrative Brain Research, Seattle, WA 98101.ORCID 0009-0002-9786-4333
Simon Du *Seattle Children's Research Institute, Norcliffe Foundation Center for Integrative Brain Research, Seattle, WA 98101.ORCID 0009-0006-9556-1995
Henry Tan *Seattle Children's Research Institute, Norcliffe Foundation Center for Integrative Brain Research, Seattle, WA 98101.ORCID 0009-0006-3600-9279
Sri Yellampally *Seattle Children's Research Institute, Norcliffe Foundation Center for Integrative Brain Research, Seattle, WA 98101.ORCID 0009-0007-7785-1865
Anders W Erickson *The Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, ON M5G0A4, Canada.ORCID 0000-0002-6134-7812
Virginia FernandezInstituto de Neurociencias, Consejo Superior de Investigaciones Científicas & Universidad Miguel Hernández, Sant Joan d'Alacant 03550, Spain.
Ferechte Encha-RazaviAssistance Publique Hôpitaux de Paris, Hôpital Necker-Enfants Malades, Paris 75015, France.ORCID 0000-0001-8656-9019
Kimberley A PhillipsSouthwest National Primate Research Center, Texas Biomedical Research Institute, San Antonio, TX 78227.ORCID 0000-0002-5517-3596
Christine HaberlerDivision of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, Vienna 1090, Austria.ORCID 0000-0003-1016-0545
Nicole AmbergDivision of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, Vienna 1090, Austria.ORCID 0000-0002-3183-8207
Victor BorrellInstituto de Neurociencias, Consejo Superior de Investigaciones Científicas & Universidad Miguel Hernández, Sant Joan d'Alacant 03550, Spain.ORCID 0000-0002-7833-3978
Paul A NorthcottCenter of Excellence in Neuro-Oncology Sciences, St. Jude Children's Research Hospital, Memphis, TN 38105.
Michael D TaylorThe Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, ON M5G0A4, Canada.
Kathleen J MillenSeattle Children's Research Institute, Norcliffe Foundation Center for Integrative Brain Research, Seattle, WA 98101.ORCID 0000-0001-9978-675X
Parthiv HaldipurSeattle Children's Research Institute, Norcliffe Foundation Center for Integrative Brain Research, Seattle, WA 98101.ORCID 0000-0003-2865-8683
Funding
Mouse models to discover new drivers of medulloblastomaR01CA159859 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI Michael D. Taylor, WILLIAM A WEISS · 2011 to 2026
$10.4M
Pathological Mechanisms of Human Cerebellar MalformationsR37NS095733 · NINDS · SEATTLE CHILDREN'S HOSPITAL · PI Kathleen Joyce Millen · 2021 to 2026
$5.5M
CCL2 and CCR2 as metastatic drivers and therapeutic targets in medulloblastomaR01CA255369 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GARZIA, LIVIA, TAYLOR, MICHAEL D. · 2021 to 2025
$3.9M
Pathological Mechanisms of Human Cerebeller MalformationsR01NS095733 · NINDS · SEATTLE CHILDREN'S HOSPITAL · PI MILLEN, KATHLEEN JOYCE · 2016 to 2020
$3.0M
Prevention and treatment of lethal metastases in group 3 medulloblastomaR01NS106155 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI TAYLOR, MICHAEL D., WEISS, WILLIAM A · 2018 to 2022
$2.8M
Mapping the Cerebellar Origins of Medulloblastoma SubgroupsR01CA270785 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Paul Northcott · 2023 to 2026
$2.8M
Congenital brain malformations caused by aberrant head mesenchymal signalingR01NS080390 · NINDS · SEATTLE CHILDREN'S HOSPITAL · PI MILLEN, KATHLEEN JOYCE · 2012 to 2016
$2.3M
Defining human-specific rhombic lip developmental mechanismsR21NS133390 · NINDS · SEATTLE CHILDREN'S HOSPITAL · PI HALDIPUR, PARTHIV · 2023 to 2023
$541k
Investigating Cerebellar Development in Ferrets: Implications for Modelling Human Cerebellar Development and DiseaseR21NS142543 · NINDS · SEATTLE CHILDREN'S HOSPITAL · PI HALDIPUR, PARTHIV · 2025 to 2025
$516k
High resolution analysis of human cerebellar neurogenesisR21NS117848 · NINDS · SEATTLE CHILDREN'S HOSPITAL · PI HALDIPUR, PARTHIV · 2021 to 2022
$514k
In vitro approaches to study human cerebellar developmentR21NS138661 · NINDS · SEATTLE CHILDREN'S HOSPITAL · PI HALDIPUR, PARTHIV · 2024 to 2024
$479k
HHS | NIH | National Institute of Neurological Disorders and Stroke (NINDS) R21NS117848HHS | NIH | National Institute of Neurological Disorders and Stroke (NINDS) R21NS133390HHS | NIH | National Institute of Neurological Disorders and Stroke (NINDS) R21NS138661HHS | NIH | National Institute of Neurological Disorders and Stroke (NINDS) R21NS142543HHS | NIH | National Institute of Neurological Disorders and Stroke (NINDS) R37NS095733HHS | NIH | NCI | Division of Cancer Prevention, National Cancer Institute (DCP, NCI) CA270785NCI NIH HHS R01 CA159859NCI NIH HHS R01 CA255369NCI NIH HHS R01 CA270785NINDS NIH HHS R01 NS080390NINDS NIH HHS R01 NS095733NINDS NIH HHS R01 NS106155NINDS NIH HHS R21 NS117848NINDS NIH HHS R21 NS133390NINDS NIH HHS R21 NS138661NINDS NIH HHS R21 NS142543NINDS NIH HHS R37 NS095733
6 · The paper itself
Abstract
Bergmann glia (BG) are a specialized glial population essential for cerebellar development, yet their developmental timeline and molecular identity in the human cerebellum remain poorly understood. Here, we combined detailed histopathological analysis with spatial transcriptomics and single-nucleus RNA sequencing to generate a developmental atlas of human cerebellar BG. Histology revealed that BG emerge around 11 postconception weeks (PCW), initially serving as a scaffold for Purkinje cells (PCs) migrating into the PC layer of the cerebellar cortex. Following the establishment of a multilayered PC arrangement, BG form a distinct parallel layer separated from the PCs by the lamina dissecans (LD), with both layers merging in the third trimester. This developmental sequence challenges earlier studies that suggested BG appear late in the third trimester. Comparative histology in mice, ferrets, and marmosets indicates that this trilaminar organization, including the LD, is likely unique to humans. Integration of spatial and single-nucleus transcriptomic datasets identified an
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Spatiotemporal histogenesis of the developing human cerebellum reveals dynamic layering of Bergmann glia. · full record | Socratic